Novo Nordisk won CFDA approval for its latest diabetes treatment, Tresiba, in China. The Danish company said Tresiba is a once-daily injection that controls blood sugar levels in both type 1 and type 2 diabetics. Novo Nordisk compared Tresiba, an insulin deduglec, to insulin glargines such as Lantus from Sanofi. The two drugs, both injected once-daily, are equally effective, but Tresiba has a lower chance of causing hypoglycemia, it said. Novo Nordisk has long been active in China. More details....
Related Biotechnology, Pharmaceutical and Healthcare News
The Top 100 Pharmaceutical Companies Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015
2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars)
Johnson & Johnson, U.S.
74...
Nutrition Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
